Unique ID issued by UMIN | UMIN000037615 |
---|---|
Receipt number | R000042886 |
Scientific Title | The effect of selective PPAR-alpha modulator to Non alcoholic fatty liver disease with dyslipidemia. |
Date of disclosure of the study information | 2019/10/01 |
Last modified on | 2021/08/09 11:40:56 |
The effect of selective PPAR-alpha modulator to Non alcoholic fatty liver disease with dyslipidemia.
The effect of selective PPAR-alpha modulator to Non alcoholic fatty liver disease with dyslipidemia.
The effect of selective PPAR-alpha modulator to Non alcoholic fatty liver disease with dyslipidemia.
The effect of selective PPAR-alpha modulator to Non alcoholic fatty liver disease with dyslipidemia.
Japan |
Non alcoholic fatty liver disease
Hepato-biliary-pancreatic medicine |
Others
NO
The effect of SPAARM alpha on NAFLD with dyslipidemia
Safety,Efficacy
The change in ALT at 12 weeks after medication
Observational
20 | years-old | <= |
80 | years-old | > |
Male and Female
The patients with NAFLD shown ALT>31 U/L and TG>150mg/dL
patients with cirrhosis
patients with gallstones
patients administered fibrate
50
1st name | Kanji |
Middle name | |
Last name | Yamaguchi |
Kyoto Prefectural University of Medicine
Department of Molecular Gastroenterology and Hepatology
6028566
465 kajiityou, kamigyo-ku, kyoto
0752515519
yuyaseko@koto.kpu-m.ac.jp
1st name | Yuya |
Middle name | |
Last name | Seko |
Kyoto Prefectural University of Medicine
Department of Molecular Gastroenterology and Hepatology
6028566
465 kajiityou, kamigyo-ku, kyoto
0752515519
yuyaseko@koto.kpu-m.ac.jp
Kyoto Prefectural University of Medicine
Kyoto Prefectural University of Medicine
Other
Kyoto Prefectural University of Medicine
465 kajiityou, kamigyo-ku, kyoto
0752515519
yuyaseko@koto.kpu-m.ac.jp
NO
2019 | Year | 10 | Month | 01 | Day |
Published
20
2020 | Year | 08 | Month | 10 | Day |
Completed
2019 | Year | 08 | Month | 06 | Day |
2019 | Year | 09 | Month | 24 | Day |
2019 | Year | 09 | Month | 24 | Day |
2022 | Year | 03 | Month | 31 | Day |
We analyse the change in ALT, TG, and fibroscan in NAFLD patients with hyperlipidemia after 12weeks administration of pemmafibrate.
2019 | Year | 08 | Month | 06 | Day |
2021 | Year | 08 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000042886
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |